CHI-541

**CHI-541** is an investigational oral standardized cannabis extract supplied as an oil softgel. Each softgel contains approximately 2.5 mg total tetrahydrocannabinol and less than 0.25 mg cannabidiol, corresponding to an approximately 26:1 tetrahydrocannabinol-to-cannabidiol ratio. It was evaluated by Spectrum Therapeutics in a randomized, double-blind, placebo-controlled Phase 1a multiple-dose study in healthy adults, with proposed therapeutic applications including pain, nausea, muscle spasticity, and epilepsy. Its pharmacology is expected to be driven predominantly by tetrahydrocannabinol-mediated partial agonism of cannabinoid receptors 1 and 2. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378769))